Participants 85 135 5
patients with diabetes mellitus in the LIFE-study]
Participants 239 289 5
patients with hypertension and diabetes is unclear
Participants 364 448 4
osartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.
Participants 449 856 14
MATERIAL AND METHODS A total of 1195 patients in the LIFE-study had diabetes at the time of the randomisation. The patients were randomised for double-blind treatment with losartan versus atenolol. The patients had ECG-verified left ventricular hypertrophy, mean age 67 years, blood pressure 177/96 mmHg after two weeks placebo run-in period. Patients were followed for at least four years (mean 4.7 years).
Participants 955 1062 3
Blood pressure was reduced to 146/79 and 148/79 in losartan-treated patients and atenolol-treated patients,
Participants 1081 1185 4
primary endpoint occurred in 103 patients assigned losartan (n = 586) and 139 assigned atenolol (n = 609
Participants 1555 1595 4
patients with hypertension and diabetes.
